Showing results (41-50 of 113) with videos related to

Sort By:
Pageof 12
Investigational New Drugs|August 5, 2004
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignanciesGarry H Schwartz, Christopher B Jones, Mitchell Garrison, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2008
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignanciesMonica Mita, Alain Mita, John Sarantopoulos, et al.
American Journal of Clinical Oncology|February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumorsA Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumorsQuincy Chu, Alain Mita, Bahram Forouzesh, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogueCarlton K K Lee, Eric K Rowinsky, Jing Li, et al.
Investigational New Drugs|June 2, 2011
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaAndrew H Ko, Hagop Youssoufian, Jayne Gurtler, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2006
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trialTomislav Dragovich, Mark Huberman, Daniel D Von Hoff, et al.
Investigational New Drugs|December 18, 2009
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trialSimon Pacey, Mark J Ratain, Keith T Flaherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerRomán Pérez-Soler, Abraham Chachoua, Lisa A Hammond, et al.
Pageof 12